ライフサイエンスコーパス: T-cell lymphoma

1 on of immature thymocytes and development of T cell lymphoma.

2 inhibitors that are efficacious in cutaneous T cell lymphoma.

3 eatment of persistent or recurrent cutaneous T cell lymphoma.

4 ymphoma, follicular lymphoma, and peripheral T-cell lymphoma.

5 ymphoma and large-cell transformed cutaneous T-cell lymphoma.

6 (MF) is the most frequent form of cutaneous T-cell lymphoma.

7 tory Hodgkin's lymphoma and anaplastic large-T-cell lymphoma.

8 sis fungoides, a common variant of cutaneous T-cell lymphoma.

9 activity in large-cell transformed cutaneous T-cell lymphoma.

10 could have a critical role in the biology of T-cell lymphoma.

11 a condensin II subunit (Caph2(nes)) develop T-cell lymphoma.

12 es that demonstrated preliminary activity in T-cell lymphoma.

13 dy, in 41 pretreated patients with cutaneous T-cell lymphoma.

14 ggressive CD4+ leukemic variant of cutaneous T-cell lymphoma.

15 ymphoma, and four of eight with noncutaneous T-cell lymphoma.

16 drug approved for the treatment of cutaneous T-cell lymphoma.

17 se agents to treat skin cancer and cutaneous T-cell lymphoma.

18 ymphoma, Burkitt's lymphoma, or noncutaneous T-cell lymphoma.

19 pGs have demonstrated efficacy for cutaneous T-cell lymphoma.

20 h, including atopic dermatitis and cutaneous T-cell lymphoma.

21 ncer, lentigo maligna melanoma and cutaneous T-cell lymphoma.

22 ositive, anaplastic lymphoma kinase-negative T-cell lymphoma.

23 in patients with PTCL than in those with non-T-cell lymphoma.

24 me are the most common subtypes of cutaneous T-cell lymphoma.

25 safety and activity of IPH4102 in cutaneous T-cell lymphoma.

26 versus ABCG2(-) non-CSCs from primary human T-cell lymphoma.

27 s with peripheral (PTCL) or cutaneous (CTCL) T-cell lymphoma.

28 es the second most common group of cutaneous T-cell lymphoma.

29 large cell lymphoma (ALCL) compared to other T cell lymphomas.

30 gnancies and is prevalent in both B cell and T cell lymphomas.

31 cell leukemia/lymphoma, and other peripheral T-cell lymphomas.

32 reated patients with CD30-positive cutaneous T-cell lymphomas.

33 ential future treatment option for cutaneous T-cell lymphomas.

34 patients with relapsed or refractory B- and T-cell lymphomas.

35 gkin lymphomas and systemic anaplastic large T-cell lymphomas.

36 cell leukaemia-lymphoma and other peripheral T-cell lymphomas.

37 icularly frequent in all forms of gammadelta-T-cell lymphomas.

38 3 expression developed colitis and alphabeta T-cell lymphomas.

39 ate safety and efficacy in CD30(+) cutaneous T-cell lymphomas.

40 and the role EBV plays in the development of T-cell lymphomas.

41 ne mechanism for the association of EBV with T-cell lymphomas.

42 n changing the natural history of peripheral T-cell lymphomas.

43 lators that are required for the survival of T-cell lymphomas.

44 (MF), the most common subtypes of cutaneous T-cell lymphomas.

45 or the treatment of CD30-positive peripheral T-cell lymphomas.

46 ukemia (T-ALL) and in a subset of peripheral T-cell lymphomas.

47 ne in mice gives rise to spontaneous thymic (T-cell) lymphomas.

48 lymphomas (6.3%) of which angioimmunoblastic T-cell lymphomas (2.3%) were the most frequent, and muco

49 lymphoma and one [2%] with anaplastic large-T-cell lymphoma; 28 [43%] during phase 1 and 37 [57%] du

50 classic Hodgkin lymphomas (13%), peripheral T-cell lymphomas (6.3%) of which angioimmunoblastic T-ce

51 ntriguing model for miR therapy is cutaneous T-cell lymphoma, a rare disease featuring malignant CD4(

52 1 (50%) samples from patients with cutaneous T-cell lymphoma, accounting for 7-18,155 cells/mul and i

53 ngioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphoma, and oth

54 present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL

55 Angioimmunoblastic T-cell lymphoma (AITL) and other lymphomas derived from

56 ons among 3 patients with angioimmunoblastic T-cell lymphoma (AITL) and single patients with multiple

57 The genetics of angioimmunoblastic T-cell lymphoma (AITL) are very poorly understood.

58 Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature

59 L-entities, including 114 angioimmunoblastic T-cell lymphoma (AITL), 31 anaplastic lymphoma kinase (A

60 However, in angioimmunoblastic T-cell lymphoma (AITL), mutations are almost exclusively

61 of IDH2R172 mutations in angioimmunoblastic T-cell lymphoma (AITL).

62 and a lower incidence of angioimmunoblastic T-cell lymphoma (AITL); Asians/Pacific Islanders had a h

63 Ls; n = 35), specifically angioimmunoblastic T-cell lymphoma (AITL; n = 13) and PTCL not otherwise sp

64 on-Hodgkin, Hodgkin and nasal natural killer/T-cell lymphomas, although all three TET family genes ar

65 med relapsed or refractory primary cutaneous T-cell lymphoma, an Eastern Cooperative Oncology group p

66 In T-cell lymphomas, anaplastic large-cell lymphoma is defi

67 e that WASP and WIP are tumor suppressors in T cell lymphoma and suggest that MAP-kinase kinase (MEK)

68 location was found in a subset of peripheral T cell lymphomas and was shown to result in an IL-2-indu

69 assification, primary cutaneous acral CD8(+) T-cell lymphoma and Epstein-Barr virus positive (EBV(+))

70 umor effect of rapamycin in a mouse model of T-cell lymphoma and examine the metabolic effects in vit

71 eneration proteasome inhibitor, ixazomib, in T-cell lymphoma and Hodgkin lymphoma cells and in vivo S

72 ibited tumor growth and improved survival in T-cell lymphoma and Hodgkin lymphoma human lymphoma xeno

73 n shown to be important for cell survival in T-cell lymphoma and Hodgkin lymphoma models.

74 gulates MYC and induces potent cell death in T-cell lymphoma and Hodgkin lymphoma, and we identified

75 lastic cells in primary cutaneous anaplastic T-cell lymphoma and large-cell transformed cutaneous T-c

76 squamous cell cancers, as well as cutaneous T-cell lymphoma and lentigo maligna melanoma.

77 ons in DNMT3A have been recently reported in T-cell lymphoma and leukemia, implying a possible involv

78 both active and well tolerated in cutaneous T-cell lymphoma and lymphomatoid papulosis, with an over

79 (MF) is the most common subtype of cutaneous T-cell lymphoma and may rarely infiltrate the ocular str

80 f AITL, extranodal nasal-type natural killer/T-cell lymphoma and NK-cell leukemia (ENKCL), and ATLL a

81 In MDV-induced T-cell lymphomas and in lymphoblastoid cell lines derive

82 oncogenic gammaherpesvirus that causes acute T-cell lymphomas and leukemias in New World primates and

83 l of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and LyP from 2011 to 2013.

84 logs are effective in treating leukemias and T cell lymphomas, and 6-ETI may fill this niche for the

85 acute lymphoblastic leukemia, natural killer/T-cell lymphoma, and acute myeloid leukemia, as well as

86 not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic lymphoma kinase (ALK)-ne

87 cell proliferation in dermatitis, cutaneous T-cell lymphoma, and graft-versus-host disease.

88 with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti-

89 r lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, and non-Hodgkin lymphoma not otherwise

90 treatment of relapsed/refractory peripheral T-cell lymphoma, and often used in combination with chem

91 rface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form

92 mor immunity in primary cutaneous anaplastic T-cell lymphoma, and provide a rationale for the pharmac

93 after chemotherapy for an angioimmunoblastic-T-cell-lymphoma, and thirty-three hours after being stru

94 Cutaneous T-cell lymphomas are rare, generally incurable, and asso

95 Boxers, which develop aggressive T-cell lymphomas, are typically mutated in the PTEN-mTOR

96 n promotes genomic instability that leads to T-cell lymphomas as a consequence of altered double stra

97 MDV-miR-M4 is critical for the induction of T-cell lymphomas as mutant viruses with precise deletion

98 P for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement i

99 s to compare in a large series of peripheral T cell lymphoma, as a model of diffuse disease, the prog

100 stic large cell lymphoma (BIA-ALCL), a CD30+ T-cell lymphoma associated with textured breast implants

101 HTLV-1)-associated adult T-cell leukemia and T-cell lymphoma (ATL) are aggressive diseases with poor

102 roved for relapsed and refractory peripheral T-cell lymphomas based on their activity, although they

103 howing that ITK-Syk expression causes clonal T cell lymphoma by 20-27 wk of age, we investigated the

104 xample, one-third of patients with EBV(+) NK/T-cell lymphoma carried two novel nonsense variants (Q32

105 In a cutaneous T-cell lymphoma cell line, promoter hypermethylation was

106 cycle arrest in primary cutaneous anaplastic T-cell lymphoma cells in vitro and a xenograft model in

107 yndrome is a rare leukemic form of cutaneous T cell lymphoma characterized by generalized redness, sc

108 Primary cutaneous anaplastic T-cell lymphoma, characterized by the CD30+ anaplastic l

109 r early-stage nasal type natural killer (NK)/T-cell lymphoma, combined radiotherapy (RT), and chemoth

110 cell lymphomas constituted 99% (n = 258) and T-cell lymphomas constituted 1% (n = 2).

111 -cell lymphomas constituted 83% (n = 71) and T-cell lymphomas constituted 17% (n = 15).

112 namics of active regulatory DNA in cutaneous T cell lymphoma (CTCL) by ATAC-seq.

113 In this article, we report that cutaneous T cell lymphoma (CTCL) cells and tissues ubiquitously ex

114 Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin

115 a leukemic and aggressive form of cutaneous T cell lymphoma (CTCL) resulting from the malignant tran

116 hallmark of the advanced stages of cutaneous T cell lymphoma (CTCL), where it has been associated wit

117 rome (SS) is a leukemic variant of cutaneous T-cell lymphoma (CTCL) and represents an ideal model for

118 Patients with cutaneous T-cell lymphoma (CTCL) are frequently colonized with Sta

119 Therapeutic options for cutaneous T-cell lymphoma (CTCL) are limited and curative treatmen

120 ry syndrome are two major forms of cutaneous T-cell lymphoma (CTCL) characterized by resistance to ap

121 cent years, a curative therapy for cutaneous T-cell lymphoma (CTCL) has not yet been developed.

122 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of malig

123 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of prima

124 Cutaneous T-cell lymphoma (CTCL) is an aggressive neoplasm with li

125 Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymph

126 Cutaneous T-cell lymphoma (CTCL) is characterized by proliferation

127 ell lymphoma line, MBL2, and human cutaneous T-cell lymphoma (CTCL) lines, HH and Hut78, were used in

128 Importance: Cutaneous T-cell lymphoma (CTCL) of the hands and feet can be chal

129 blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinical outcome.

130 Advanced cutaneous T-cell lymphoma (CTCL) remains an unmet medical need, wh

131 red to six healthy control and six cutaneous T-cell lymphoma (CTCL) samples from previously published

132 NA) dysregulation is a hallmark of cutaneous T-cell lymphoma (CTCL), an often-fatal malignancy of ski

133 fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), as compared to normal skin or be

134 The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sezary syndrome and my

135 S Food and Drug Administration for cutaneous T-cell lymphoma (CTCL), including the leukemic subtype S

136 is fungoides (MF), the most common cutaneous T-cell lymphoma (CTCL), is unknown.

137 The pathogenesis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is uncle

138 itor approved for the treatment of cutaneous T-cell lymphoma (CTCL).

139 ) is frequently mutated in primary cutaneous T-cell lymphoma (CTCL).

140 liferation, and tumor formation in cutaneous T-cell lymphoma (CTCL).

141 epression in an aggressive form of cutaneous T-cell lymphoma (CTCL).

142 own about their pathogenic role in cutaneous T-cell lymphoma (CTCL).

143 ssion in models of skin cancer and cutaneous T-cell lymphoma (CTCL).

144 urther detected in a proportion of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides skin samples an

145 and for monitoring progression of cutaneous T-cell lymphoma (CTCL)/SS and that FCRL3 expression corr

146 1 is FDA-approved for treatment of cutaneous T-cell lymphoma (CTCL); however, 1 can provoke side effe

147 syndrome comprise the majority of cutaneous T cell lymphomas (CTCLs), disorders notable for their cl

148 Cutaneous T-cell lymphomas (CTCLs) are a family of primary extrano

149 Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of di

150 Cutaneous T-cell lymphomas (CTCLs) form a heterogeneous group of n

151 Cutaneous T-cell lymphomas (CTCLs) primarily affect skin and are c

152 Cutaneous T-cell lymphomas (CTCLs) represent a group of hematopoie

153 diseases, the malignant T cells of cutaneous T-cell lymphomas (CTCLs), such as Sezary syndrome, displ

154 een shown to be hypermethylated in cutaneous T-cell lymphomas (CTCLs), using standard bisulfite modif

155 stic large-cell lymphoma, angioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma, adult T-cell

156 In a mouse model of T cell lymphoma driven by TET deficiency (Tet2/3 DKO T c

157 led the progression of OVA257-264 expressing T-cell lymphoma EG7 (injected intradermally), the deplet

158 linical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has improved substantially as a

159 Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological

160 In a model of cutaneous T cell lymphoma, epidermotropic CD4(+) TRM lymphoma cell

161 report about the function of TLR3 in chicken T-cell lymphoma, especially in signal pathway.

162 arcinomas, e.g. diffuse large B cell tumors, T cell lymphomas, etc.

163 In contrast, T-cell lymphomas from the predisposed breeds, boxers and

164 investigated the somatic mutations in B- and T-cell lymphomas from these breeds by exome sequencing o

165 niel), and with equal distribution of B- and T-cell lymphoma (golden retriever), respectively.

166 s immune-mediated diseases such as cutaneous T cell lymphoma, graft-versus-host disease, and organ al

167 ctory Hodgkin's lymphoma or anaplastic large-T-cell lymphoma, had biopsy-proven CD30-positive tumours

168 Of the haematological malignancies, T-cell lymphomas have an extremely poor prognosis.

169 f T-cell diseases, including some peripheral T-cell lymphomas, hemophagocytic lymphohistiocytosis, an

170 EBV is associated with a number of T-cell lymphomas; however, in vitro studies utilizing pr

171 Hepatosplenic T-cell lymphoma (HSTCL) is a rare T-cell neoplasm that m

172 rkitt's lymphoma in humans and hepatosplenic T cell lymphomas in mice.

173 D and monomorphic epitheliotropic intestinal T-cell lymphoma in humans.

174 a potent oncogenic herpesvirus that induces T-cell lymphoma in infected chickens.

175 chemotaxis of monocytes in a syngeneic mouse T-cell lymphoma in skin.

176 V) is an alphaherpesvirus that causes deadly T-cell lymphomas in chickens and serves as a natural sma

177 T-cell lymphomas in golden retrievers are often less agg

178 n excellent model for studying virus-induced T-cell lymphomas in the natural chicken hosts.

179 ancy in the thymus and development of CD4(+) T-cell lymphomas in the periphery.

180 We also examine T-cell lymphomas, including anaplastic large-cell lympho

181 cellular localization of the actin regulator T cell lymphoma Invasion And Metastasis 1 (TIAM-1), ther

182 T-cell lymphoma invasion and metastasis 1 (Tiam1) is a D

183 e the levels of Rac1-GTP and the activity of T-cell lymphoma invasion and metastasis 1 (TIAM1), a Rac

184 Tiam1 (T-cell lymphoma invasion and metastasis 1) is a guanine

185 thelial cell transforming squence 2), Tiam1 (T-cell lymphoma invasion and metastasis 1), Vav and P-Re

186 Cutaneous T-cell lymphoma is a form of non-Hodgkin lymphoma that m

187 Cutaneous T-cell lymphoma is a heterogeneous group of lymphomas ch

188 diffuse large B-cell lymphoma and peripheral T-cell lymphoma is potential cure, during which PET is m

189 Peripheral blood involvement by cutaneous T-cell lymphoma is typically assessed by flow cytometry

190 cell lymphoma (BIA-ALCL), a rare peripheral T-cell lymphoma, is increasing in incidence.

191 acid is already approved to treat cutaneous T-cell lymphoma, it could potentially be used as a thera

192 e broader category of the disease-peripheral T-cell lymphoma-let alone any of the specific subtypes,

193 T-cell lymphoma (n = 9), tMF (n = 7), adult T-cell lymphoma/leukemia (n = 4), anaplastic large-cell

194 mphocytopenia and greatly increased risk for T-cell lymphomas/leukemia.

195 The murine T-cell lymphoma line, MBL2, and human cutaneous T-cell l

196 found that Notch signaling represses Ccr9 in T cell lymphoma lines in which Ccr9 transcription is ind

197 ell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma lines in vitro and significantly inhibit

198 of origin and lymphocyte ontogeny among the T-cell lymphomas may improve our understanding of the tu

199 ts with stage IA through stage IIA cutaneous T-cell lymphoma, MF type, to evaluate treatment using to

200 large cell lymphoma (ALCL) is an aggressive T-cell lymphoma most commonly seen in children and young

201 ma radiation (IR)-induced replication stress T-cell lymphoma mouse model, we observed a significant i

202 stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted i

203 phoma (n = 2), and extranodal natural killer/T-cell lymphoma (n = 2).

204 ded DLBCL (n = 21), MCL (n = 13), peripheral T-cell lymphoma (n = 8), transformed follicular lymphoma

205 rwise specified (n = 13), angioimmunoblastic T-cell lymphoma (n = 9), tMF (n = 7), adult T-cell lymph

206 sis (n = 9) and primary cutaneous anaplastic T-cell lymphomas (n = 2) responded; time to response was

207 5B in NK/T-cell lymphomas (n=51), gammadelta-T-cell lymphomas (n=43) and their cell lines (n=9) throu

208 tivating mutations of STAT3 and STAT5B in NK/T-cell lymphomas (n=51), gammadelta-T-cell lymphomas (n=

209 = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; m

210 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27).

211 Natural killer/T cell lymphoma (NKTCL) is a rare and aggressive maligna

212 transcriptional landscape of natural killer/T cell lymphoma (NKTCL), a rare form of non-Hodgkin's ly

213 Natural killer/T-cell lymphoma (NKTCL) is a rare, aggressive form of no

214 Extranodal natural killer-T-cell lymphoma (NKTCL) of nasal type is a malignant dis

215 Extranodal natural killer T-cell lymphoma (NKTCL), nasal type, is a rare and aggre

216 Extranodal natural killer T-cell lymphoma (NKTCL; nasal type) is an aggressive mal

217 In the current study, using natural killer/T-cell lymphoma (NKTL) as a disease model, we found that

218 cancers including extranodal natural killer/T-cell lymphoma (NKTL).

219 The most common PTCLs, peripheral T-cell lymphoma, not otherwise specified, angioimmunobla

220 Peripheral T-cell lymphoma, not otherwise specified, is a broad cat

221 ungoides, and one (2%) had primary cutaneous T-cell lymphoma, not otherwise specified.

222 Marek's disease (MD) is a T cell lymphoma of chickens induced by Marek's disease v

223 L and NSCLC, as compared with other types of T-cell lymphoma or EGFR- and K-RAS-mutated NSCLC, respec

224 Deletion of Mdm2 in T-cell lymphomas or sarcomas lacking p53 induced apoptos

225 ll responses were associated with peripheral T-cell lymphoma (OR = 2.14, 95% CI: 1.35, 3.38).

226 tients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sezary syndrome

227 g pathway previously implicated in cutaneous T-cell lymphoma pathogenesis, JAK/STAT signaling, we use

228 in 252 nodal PTCL and enteropathy-associated T-cell lymphoma patients (excluding anaplastic lymphoma

229 verall response rate in all, non-T-cell, and T-cell lymphoma patients was 32%, 10%, and 73%, respecti

230 n of mogamulizumab is warranted in cutaneous T-cell lymphoma patients.

231 Primary cutaneous gammadelta T cell lymphomas (PCGDTLs) represent a heterogeneous gro

232 c large cell lymphoma (ALCL) is a peripheral T-cell lymphoma presenting mostly in children and young

233 The hallmark of cutaneous T-cell lymphoma progression is epigenetic dysregulation,

234 atment of immunodeficient mice bearing human T cell lymphomas promoted tumor cell apoptosis and tumor

235 c leukemia (CLL) and CD8-positive peripheral T cell lymphomas (PTCL) in EmuSRalpha-tTA;Teto-Cre;Dnmt3

236 Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group

237 Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggre

238 Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of matur

239 T-cell clonality of peripheral T-cell lymphoma (PTCL) is routinely evaluated with a PCR

240 is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL).

241 little is known about the risk in peripheral T-cell lymphoma (PTCL).

242 dotin (BV) in relapsed/refractory peripheral T-cell lymphoma (PTCL).

243 Peripheral T-cell lymphomas (PTCL) are a group of rare malignancies

244 Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poo

245 Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such as cyclop

246 Peripheral T cell lymphomas (PTCLs) are a heterogeneous and poorly

247 Peripheral T cell lymphomas (PTCLs) are a heterogeneous entity of n

248 Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of or

249 Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of no

250 Peripheral T-cell lymphomas (PTCLs) are rare lymphomas with mostly

251 The peripheral T-cell lymphomas (PTCLs) are uniquely sensitive to epige

252 The peripheral T-cell lymphomas (PTCLs) encompass a heterogeneous group

253 Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavi

254 Peripheral T-cell lymphomas (PTCLs) represent a diverse group of no

255 ) represent a large proportion of peripheral T-cell lymphomas (PTCLs) with poorly understood pathogen

256 eported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy.

257 emain elusive for the most common peripheral T-cell lymphomas (PTCLs).

258 ed a new era in the management of peripheral T-cell lymphomas (PTCLs).

259 t analysis included patients with peripheral T-cell lymphomas (PTCLs; n = 35), specifically angioimmu

260 ukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dose-limiting

261 tically accelerated incidence of both B- and T-cell lymphomas relative to Emu-D1T286A or ATM-/- contr

262 are limited, and the genetic basis of these T cell lymphomas remains incompletely characterized.

263 lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively.

264 eity in chromosome instability-driven murine T-cell lymphoma samples, indicating ongoing chromosome i

265 4(+) T-cell subsets from 86 patients without T-cell lymphoma showed polytypic TRBC1 staining, except

266 utely transforming retrovirus AKT8 in rodent T-cell lymphoma/signal transducer and activator of trans

267 utely transforming retrovirus AKT8 in rodent T-cell lymphoma signaling.

268 city of cases, and the absence of peripheral T-cell lymphoma-specific drugs, until recently at least,

269 One hundred six patients with peripheral T cell lymphoma, staged with PET/CT, were enrolled from

270 frequent than CDKN2A (12%) in all cutaneous T-cell lymphoma stages using quantitative reverse transc

271 The specific role of MTAP in cutaneous T-cell lymphoma subgroups, mycosis fungoides (MF) and Se

272 Global overall response by cutaneous T-cell lymphoma subtype was a secondary endpoint.

273 the pathological and clinical aspects of the T-cell lymphoma subtypes as well as NK-cell lymphomas an

274 -cell leukaemia-lymphoma or other peripheral T-cell lymphoma subtypes, and at least one previous anti

275 reviously untreated CD30-positive peripheral T-cell lymphomas (targeting 75% with systemic anaplastic

276 in the absence of gene amplification, e.g., T cell lymphoma (TCL).

277 vitro and in vivo activity of everolimus in T-cell lymphoma (TCL) and pave the way for future combin

278 tudy investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor

279 NHL), chronic lymphocytic leukemia (CLL), or T-cell lymphoma (TCL) were treated with 25 or 75 mg duve

280 tive against multiple cancer types including T-cell lymphoma (TCL).

281 Patients diagnosed with T-cell leukemias and T-cell lymphomas (TCLs) still have a poor prognosis and

282 e effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches

283 tivated growth-related signaling pathways in T-cell lymphomas (TCLs).

284 cell lymphoma (ALCL) is a distinct entity of T-cell lymphoma that can be divided into 2 subtypes base

285 l lymphoma (BIA-ALCL) is a very rare type of T-cell lymphoma that is uniquely caused by a single envi

286 -cell leukemia/lymphoma and 44 extranodal NK/T-cell lymphoma that were further separated into NK-cell

287 ore the role of IPH4102 in other subtypes of T-cell lymphomas that express KIR3DL2.

288 cell lymphoma (ALCL), a specific subtype of T-cell lymphoma, the Rho family GTPases Cdc42 and Rac1 a

289 is commonly observed across various types of T-cell lymphomas, the extent of deregulation is signific

290 ients with Hodgkin's lymphoma and peripheral T-cell lymphoma, treatment with bendamustine alone only

291 onstrate that rapamycin suppresses growth of T-cell lymphoma tumors and leads to a reduction in aerob

292 es (MF) is the most common primary cutaneous T-cell lymphoma variant and is closely related to a rare

293 Therefore, its role in the T-cell lymphomas was examined.

294 term "primary cutaneous CD4(+) small/medium T-cell lymphoma" was modified to "primary cutaneous CD4(

295 ll specific chromatin organizer in cutaneous T-cell lymphoma, whereas its expression and function in

296 ymphoma (breast implant ALCL) is an uncommon T cell lymphoma, which is associated with textured surfa

297 psed or refractory systemic anaplastic large-T-cell lymphoma who previously received at least one che

298 ALK was first identified in a subset of T-cell lymphomas with anaplastic large cell lymphoma (AL

299 AITL now resides under the umbrella of nodal T-cell lymphomas with follicular T helper phenotype.

300 hromatin accessibility profiles of cutaneous T cell lymphoma, with dynamic assessments of response an